Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...

Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease.

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

Accessed March 2025. 3 J&J Data on file (RF-433976). European Medicines Agency. Updated TREMFYA Summary of Product Characteristics. Accessed March 2025. 5 EU SmPC: European Medicines Agency. TREMFYA ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others during certain market conditions. Three Motley Fool contr ...